Bausch Health Companies Inc. - רווח למניה ב-12 החודשים האחרונים BHC

Bausch Health Companies (BHC) generates revenue from the sale of ophthalmology and gastroenterology products to various patient categories. Leveraging a powerful portfolio of Salix and Bausch + Lomb brands, the holding company allocates profits toward debt repayment, although massive debt continues to constrain growth. The current EPS TTM YoY growth rate on the GURU.Markets dynamic chart reflects the impact of borrowing costs, with the metric currently standing at -332.40.
Bausch Health Companies - פילוחים אנליטיים ומדדי מפתח (BHC)

Production automation at Bausch Health Companies (BHC) optimizes costs, yet the efficiency of R&D and clinical trial investments translates directly into earnings per share dynamics. Analyzing the historical percentage growth of EPS YoY (TTM) allows for an assessment of the annual change in net income over 12 months, where sharp deviations in the curve signal a risk of declining solvency for the company despite a formally low asset valuation.